3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Withdrawn
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
38
Leukemia
37
Burkitt Lymphoma
13
Lymphoma
9
Leukemia, Biphenotypic, Acute
8
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
6
Leukemia, Myeloid, Acute
6
Myelodysplastic Syndromes
4
Leukemia, Myelomonocytic, Chronic
4
Anemia, Refractory, with Excess of Blasts
4
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
3
Myeloproliferative Disorders
3
Leukemia, Monocytic, Acute
3
Down Syndrome
3
Recurrence
2
Neutropenia
2
Neoplasms
2
Neoplasm, Residual
2
Neoplasm Metastasis
2
Myelodysplastic-Myeloproliferative Diseases
2
Leukemia, Promyelocytic, Acute
2
Leukemia, Myelomonocytic, Acute
2
Leukemia, Megakaryoblastic, Acute
2
Leukemia, Erythroblastic, Acute
2
Dendritic Cell Sarcoma, Interdigitating
2
Brain Neoplasms
2
Anemia, Refractory
2
Thrombocytopenia
1
Optic Nerve Glioma
1
Lymphoma, T-Cell
1
Interventions
pembrolizumab
180
Gemcitabine
168
Paclitaxel
150
Carboplatin
134
Bevacizumab
126
Cisplatin
113
Docetaxel
112
Cyclophosphamide
109
Exercise
97
Nivolumab
93
Fluorouracil
88
Capecitabine
85
Dexamethasone
81
Irinotecan
74
Radiotherapy
68
Oxaliplatin
68
Pemetrexed
66
Standard of Care
64
Leucovorin
63
Cetuximab
59
Sorafenib
53
Erlotinib Hydrochloride
53
Drug Therapy
53
Blood Specimen Collection
51
Doxorubicin
50
atezolizumab
48
trametinib
47
Ipilimumab
47
Albumin-Bound Paclitaxel
44
130-nm albumin-bound paclitaxel
42
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasms
×
Thioguanine
×
Clear all
NCT06351306
2025-03-24
DEC-C and Thioguanine for R/R AML
Columbia University
Phase 2
Withdrawn
NCT02912676
2020-04-15
TEAM
Rigshospitalet, Denmark
Phase 1/2
Completed
30 enrolled